Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review

Abstract Occult breast cancer (OBC) signifies a rare subset of breast cancers, accounting for only 0.3 to 1% of all breast cancers. Diagnosing cancer of unknown primary requires a comprehensive approach, including histological examination, immunohistochemistry, multidisciplinary team assessments, an...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of medical and paediatric oncology
Main Authors Makwana, Ketan, Valame, Shaunak
Format Journal Article
LanguageEnglish
Published 18.07.2024
Online AccessGet full text

Cover

More Information
Summary:Abstract Occult breast cancer (OBC) signifies a rare subset of breast cancers, accounting for only 0.3 to 1% of all breast cancers. Diagnosing cancer of unknown primary requires a comprehensive approach, including histological examination, immunohistochemistry, multidisciplinary team assessments, and specialized therapy. We present the case of a postmenopausal woman diagnosed with OBC with diffuse carcinomatosis of the bone marrow (DCBM), which was hormone receptor positive and Her2neu negative. Treatment with aromatase inhibitor and the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib yielded significant clinical improvement. The full potential of this therapy warrants investigation in real-world studies.
ISSN:0971-5851
0975-2129
DOI:10.1055/s-0044-1787710